How To Run A Harvard Lab From The Battlefield

As a former major in the Rhode Island National Guard, Kevin Kit Parker has been called into duty in Afghanistan three times in the last decade. Somehow, he also finds time to run a 20-member bioengineering lab at Harvard thats innovating itself onto the cutting edge of microfluidics, tissue engineering and biomechanics. "For the last 10 years its been more than science--Ive had to fight a war at the same time." So how does he manage it all?

Busily!

In December of 2010, Parker, currently a member of the United States Army Reserve and a professor of applied mathematics at the United States Military Academy at West Point, was in Japan at a conference preparing to present his theoretical model of cell building to a room full of scientists. As his host ambled through a lengthy introduction, his BlackBerry buzzed. "While they were introducing me to give this talk I got an email saying, 'Youre going to Afghanistan next month.'"

Parker's lab (together with a Caltech group across the country) recently made headlines when they built a cyborg robot out of sheets of silicone and slices of living, lab-grown muscle, that mimicked the swimming strokes of a living jellyfish. Also on slow boil at the Parker group is research on wound-healing bandages, cellular simulators to observe the effect of blast injuries on neurons, and strong, sturdy nano fabrics spun out by what looks like a cotton candy machine. Recently, Parker was part of a Wyss Institute research team that won a $37 million DARPA grant to build a 10-organ "human on a chip" which would mimic, on a reduced scale, the physiology of the human body. In between, Parker has led counterinsurgency maneuvers in Afghanistan and used some of what he learned in the field to help Massachusetts State Police combat organized gang crime.

It comes as no surprise that Parker grew up multitasking. As a child, I played sports, and I played army and had a lab in my garage, he says. I had a Sears chemistry set. I used to scoop up dead animals and dissect them. Majors in physics and engineering led to a PhD and post doc at Vanderbilt. Parker had just secured an appointment at Harvard when he was called into Afghanistan in 2002. He told Harvard to wait a year, went out into battle, then came back to pick up his post.

Parker's first focus as a young scientist at Harvard was cardiac cell biology and tissue engineering. But he found himself getting called on by his army colleagues to study trauma effects of war on the brain. In the beginning, Parker resisted. Finally a friend of mine got wounded, Parker says, which was when he relented. "Think about this. I have all these resources available. What kind of jerk am I that I only work on the things that I want to work on?" Parker decided to focus his work on what he knew best--creating tissue-engineered sections of tissue--not of the heart, as he did in his PhD days, but of the brain.

I told DARPA, 'Listen, to do brain injury research, if I start blowing up goats in Harvard yard, Im not going to last long.' To better understand brain injuries, his first goal was to recreate, on the benchtop, the impact an explosion would have on brain tissue. And so members of Parkers lab, young veterans among them, put their heads together and combined what they knew about explosives and tissue engineering.

In September 2010, while the project was still in its early stages, Parker testified to a Congressional committee on what science knew about traumatic brain injuries. The issue is a complex and understudied scientific problem because, Parker said, "It can require a knowledge of explosives, shock physics, cell and tissue mechanics, molecular biology, neurobiology, psychology, and neurodegenerative diseases. I am not an expert in any of these fields, but I know a few words from each and that might be about as good as it gets."

The result is what Parker calls a concussion on a chip--a scaled-down explosion applied to a lab-grown bit of brain tissue. We hit paydirt, he says of the two papers the group published in 2011. I think we had a really big breakthrough. Everyone was excited because it pointed to some drug targets some pathways that were interesting based on what we found an explosion might feel like to a neuron.

The composition of Parker's lab group reflects his enthusiasm for collaborative, interdisciplinary research. It relies on the wide-ranging skills of biologists, chemists, engineers, and even employed a dentist at one point. Weve got a lot of crazy cats in there, Parker says. In fact, that's his recipe to stay ahead: "The cutting edge of a field is often putting two fields together--things that don't belong." For example, his lab studies cells using an algorithm law enforcement agencies use to do qualitative analysis of fingerprints.

Continue reading here:
How To Run A Harvard Lab From The Battlefield

Singapore's IBN Develops Superior Fuel Cell Material

You are here : Business News

August 24, 2012 15:38 PM

Singapore's IBN Develops Superior Fuel Cell Material

SINGAPORE, Aug 24 (Bernama) -- Using a mixture of gold, copper and platinum nanoparticles, the Institute of Bioengineering and Nanotechnology (IBN) researchers have developed a more powerful and longer lasting fuel cell material.

This breakthrough was recently published in leading journal Energy and Environmental Science.

Fuel cells are a promising technology for use as a source of electricity to power electronic devices, vehicles, military aircraft and equipment.

A fuel cell converts the chemical energy from hydrogen (fuel) into electricity through a chemical reaction with oxygen, and can produce electricity continuously as long as there is a fuel supply.

Current commercially available fuel cells use platinum nanoparticles as the catalyst to speed up the chemical reaction because platinum is the only metal that can resist the highly acidic conditions inside such a cell.

-- BERNAMA

We provide (subscription-based) news coverage in our Newswire service.

Read the original post:
Singapore's IBN Develops Superior Fuel Cell Material

The Myriad Decision: When commonsense took leave of American Jurisprudence

If you thought America's problems were the first-to-invent vs. first-to-file, or the Apple-Samsung trial or the medical device tax as various golf-playing company executives and clueless Republican Congressmen from Indiana would have you believe...you are wrong. The American legal system's problem is...what appears to be a disastrous lack of baseline commonsense! Why would I go ahead and say that?

If like me, you have been reading the real news instead of Taylor Swift and the Kennedy she is dating or why Shia Labeouf and his girlfriend threw a lachrymal part on the streets, you have already heard about the Myriad decision.

Irresponsibility - A systemic problem

From Antonin Scalia to Tom Head, an otherwise inconsequential Judge in Texas who predicts a civil war if Obama is re-elected, the American Judiciary system is full of some very irresponsible individuals. The fact that the country and her future rests in the hands of such people can best be described as appalling. And now the Myriad decision comes as sound proof of what a mix of lack of scientific education, ethical responsibility combined with partisan judges can do for the future of science, technology and ultimately business in this country.

Nature is not an excuse

In the Myriad case, allowing the company to patent BRCA1 and BRCA2 the judge writing the majority opinion wrote - “Everything and everyone comes from nature, following its laws, but the compositions here are not natural products. They are the products of man, albeit following, as all materials do, laws of nature.”

If you read that as if he was interpreting that breast cancer is man-made. The statement also seems to open the doors for people to patent minor variations on naturally occurring substances. However, the problem is a bit deeper. Somehow a collective majority of judges at an appeals court don't even seem to have the level of scientific background that a 6th grader would be expected to have. 


Dangerous Precedent

This ruling sets a very dangerous precedent! If uninformed judges are allowed to get carried away and make such poor decisions, then the life sciences industry will truly be in shambles. And this is not some conspiratorial warning for the future - it is already here. Unless a full appeals board or the Supreme Court strikes it down, you will have a whole bunch of patented genes. What will this lead to? The answer is blindingly obvious:

1. Research will be stifled. If something as basic as BRCA1 or BRCA2 is patented, then who would want to continue research and drug development that influences either gene? 
2. If someone did want to conduct research, what would they have to do? License the very act of handling, using or talking about the genes from Myriad? How stupid is that?
3. It is not a stretch to conceive that people will start patenting SNPs (Single Nucleotide Polymorphisms) and make even simple diagnoses fall out of the reach of the masses. 

There are several other small and large disturbing possibilities. 

Protecting ourselves from the judges...

Now that we know a bunch of geniuses are stalking the halls of American Justice, we need to find ways to make sure that research and industry make progress despite them and not because of them: 

1. Get Congress to pass specific laws barring naturally occurring genes from being patented.

2. Carefully examine how judges get elected to the various echelons of the judiciary.

3. Establish procedures and guidelines that will quicken the process of censuring runaway judges and if possible, impeach them, or nudge them to retirement.

4. Be vigilant about for-profit companies that would constantly want to find loopholes and exploit them. This one seems so obvious, and yet, it cannot be emphasized too much. 

References:

1. http://www.nytimes.com/2012/08/17/business/court-reaffirms-right-of-myriad-genetics-to-patent-genes.html?_r=2







Source:
http://chaaraka.blogspot.com/feeds/posts/default

Bioengineering student takes out three-minute challenge

The University of Queensland's (UQ) Australian Institute for Bioengineering and Nanotechnology (AIBN) researcher Amanda Pearce is set to compete in the finals of the Three Minute Thesis competition next month.

Miss Pearce, formerly of Dalby, won UQ's Combined Institute Final of the competition hosted by UQ's Diamantina Institute for Cancer, Immunology and Metabolic Medicine on August 17.

She will represent AIBN in the UQ final on September 18.

The Three Minute Thesis competition challenges students to strip away the jargon and explain their research in a compelling way to a general audience within three minutes.

Miss Pearce was also named the People's Choice, with an explanation of her research in polymer chemistry.

When I explain my research, I want to broaden people's horizons and help find out about research, Miss Pearce said.

It is easy to underestimate Australia's research; people should know that cutting-edge research is conducted in this country.

Miss Pearce of Chapel Hill said her PhD research project involved developing a polymer system that could be used for diagnosing and treating prostate cancer.

Using hyperbranched polymers allows me to do three things: detect prostate cancer cells, introduce an imaging agent that will show up tumours in MRI scans and deliver chemotherapy medicines to kill tumours without targeting healthy cells, she said.

Even members of Miss Pearce's family found it difficult to understand her research project and were surprised that it involved opportunities for collaboration and international travel.

Go here to read the rest:
Bioengineering student takes out three-minute challenge

India’s Pharma FDI Mess…

A note: "Apothecurry" - a blog with a very creative and meaningful name is my favorite blog to get some nifty scoops  on the status of the Indian pharma industry, and I suppose what the Indian Government is doing to it...

You can find the blog linked at the end of  the post.

The question everyone wants to ask: Why is the Indian Government f*ing up the pharma industry?

Among other things they have done:

1. They forced Bayer to license a Cancer drug in a very ambiguous manner. Bayer is no saint, the proposed drug cost and their stance is a direct evidence of either greed or self-loathing inanity - hard to say.

2. They have made a pledge to provide free drugs to India's teeming millions without a proper plan or even the semblance of one...

3. Now, they have threatened Foreign Direct Investments, and, according to Apothecurry, in quite a disparate manner.

Bringing the License Raj back:

Well, not the TBBT Raj, but the much maligned "License Raj", the practice of requiring companies to obtain licenses and burying them in reams of paperwork, promoting corruption, stifling even a whiff of innovation and essentially choking an industry.

Apparently, various arms of the Indian Government have their own plans to stuff their hand in the cookie jar. First apparently the Commerce Ministry wants every foreign investor to go through an intermediary agency called the Foreign Investment Promotion Board (FIPB).

A group of folks from various ministries, on the other hand have suggested that this hell befall only those foreign investors that dare seek more than 49% of a local pharma company. Either way, this is not good news for the Indian pharma industry.

Pharmaceutical Xenophobia

As with everything else, independent India simply misunderstood and maligned Gandhi's "Swadesi" exhortation. Untimely as his death would have ever been, were he to live today, he would pooh-pooh the anti-foreigner sentiment being used to gain popularity and votes while burying real issues.

You would think in a failing economy, the Indian Government, led by none other than Manmohan Singh, famous for bailing India out of the License Raj would not even think of suggesting protectionism.

However, like any other Government, they would like to blame their failings on someone else and thus would have you believe that India's impoverished healthcare system is a consequence of unscrupulous FDI. They may be unscrupulous, yes, but the bulk of the problem, all the way from apathy to lack of vision and corruption rests solely with India.

Whither India?

Someone should tell Sonia Gandhi, Manmohan Singh and their bandwagon of daylight dreamers that the Indian economy is not on a bed of roses. Rather than ease restrictions and make it easy for investor money to flow, the Indian Government is looking to take the country back and plunge it into the same darkness as the energy grids.

If they worry foreign investors would get carried away, they should put forth legal barriers, not imbue some Russian-Venezuelan axis of Xenophobic Hell on Earth.

If this continues, we will see that India's healthcare reach suffers worse than ever, drugs get pulled off the market, or never get into the market and the industry will whither away with stiff external competition.

Reference:

http://apothecurry.wordpress.com/2012/08/08/fdi-in-pharma-another-punch/http://apothecurry.wordpress.com/2012/08/08/fdi-in-pharma-another-punch/

Source:
http://chaaraka.blogspot.com/feeds/posts/default

Four-Fingered Robot Can Replace Flashlight Batteries [Video]

The Sandia Hand

A robot that can reproduce the dexterity of the human hand remains a dream of the bioengineering profession. One new approach to achieving this goal avoids trying to replicate the intricacy of the bones, joints and ligaments that produce our most basic gestures.

A Sandia National Laboratories research team has adopted just such a strategy by designing a modular, plastic proto-hand whose electronics system is largely made from parts found in cell phones. The Sandia Hand can still perform with a high level of finesse for a robot, and is even capable of replacing the batteries in a small flashlight. It is expected to cost about $10,000, a fraction of the $250,000 price tag for a state-of-the-art robot hand today.

The researchers were able to scrimp in a number of clever ways. One was scouring the globe for the least expensive, highest-performing components like motors, gears, etcetera, says Curt Salisbury, the projects principal investigator. Another was to build the entire electronics system from commodity parts, especially those found in cell phones. We also moved from metal structural elements to plastic, being careful to design the structures so plastic would provide adequate strength.

The Sandia Hands fingers are modular and affixed to the hand frame via magnets. This gives the researchers the flexibility to design interchangeable appendages tipped with screwdrivers, flashlights, cameras and other tools. The fingers are also designed to detach automatically to avoid damage if the hand hits a wall or other solid object too hard. The researchers say the hand can even be manipulated to retrieve and reattach a fallen finger.

Replaceable Fingers

The Hands current incarnation has only four fingers, including the equivalent of an opposable thumb. It turns out that for a wide range of manipulation tasks that humans do, four fingers is enough, Salisbury says. Still, future iterations of the Hand could have any number of fingers and any arrangement of those fingers without adding much cost or complexity, he adds.

Sandia Hand control glove

Although the Hand might someday be programmed to operate autonomously, for now a human controls the device using either a sensor-laden glove or a basic control panel. The glove is a custom design that reads a persons hand posture and attempts to replicate that with the robot hand, Salisbury says. The communication protocol right now is a USB cable, but could be upgraded to include any wireless communications approach, he adds. The teams goal is to develop a glove that costs about $1,000.

At such a low cost, and with the Defense Advanced Research Projects Agency (DARPA) funding the project, the Hand might be a welcome addition to mobile robots involved in disarming and disposing of improvised explosive devices (IEDs). The U.S. military has deployed thousands of unmanned ground robots worth hundreds of millions of dollars to disarm IEDs used against troops in Afghanistan and Iraq over the past decade. Many of these devices, such as iRobots PackBot, are driven by remote control into dangerous areas where they use clamp-like metal claws to search for and dispose of bombs. A significant amount of the money spent on these battle bots goes toward spare parts to replace those damaged in the field. One of Sandias goals is to offer greater proficiency at disarming (rather than detonating) bombs.

Read the original here:
Four-Fingered Robot Can Replace Flashlight Batteries [Video]

Cheap Four-fingered Robot Hand Edges Closer To Human Dexterity

36579393 story Posted by Soulskill on Tuesday August 21, @07:20PM from the talk-to-the-hand dept. ananyo writes "A robot that can reproduce the dexterity of the human hand remains a dream of the bioengineering profession. One new approach to achieving this goal avoids trying to replicate the intricacy of the bones, joints and ligaments that produce our most basic gestures. A Sandia National Laboratories research team has adopted just such a strategy by designing a modular, plastic proto-hand whose electronics system is largely made from parts found in cell phones. The Sandia Hand can still perform with a high level of finesse for a robot, and is even capable of replacing the batteries in a small flashlight. It is expected to cost about $10,000, a fraction of the $250,000 price tag for a state-of-the-art robot hand today. The Sandia Hand's fingers are modular and affixed to the hand frame via magnets. This gives the researchers the flexibility to design interchangeable appendages tipped with screwdrivers, flashlights, cameras and other tools. The fingers are also designed to detach automatically to avoid damage if the hand hits a wall or other solid object too hard. The researchers say the hand can even be manipulated to retrieve and reattach a fallen finger. The Hand's current incarnation has only four fingers, including the equivalent of an opposable thumb. In the video with the article, the Sandia Hand demonstrates a number of capabilities, including, perhaps most impressively, dropping a AA battery into a flashlight."

God must have loved calories, she made so many of them.

Working...

Read the original post:
Cheap Four-fingered Robot Hand Edges Closer To Human Dexterity

NIH announces winners of undergraduate biomedical engineering competition

For Immediate Release August 3, 2012

On Tuesday, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced the winners in the three categories of the DEBUT challenge, a biomedical engineering design competition for teams of undergraduate students. The three categories addressed the critical needs in biomedical technology, focusing on devices for diagnostics and therapeutics as well as technology that can aid underserved populations and individuals with disabilities.

The judging was based on four criteria: the significance of the problem being addressed, the impact on potential users and clinical care, the originality of the design, and the existence of a working prototype. Each winning team will receive a $10,000 prize to be shared among the team members and will be honored at an award ceremony during the October 2012 Annual Meeting of the Biomedical Engineering Society (BMES) in Atlanta.

In the category of Diagnostic Devices the winning project was Q-Path: A Flow-Through High-Throughput Quantitative Histology Platform, submitted by Armin Arshi, David Kuo, Robert Lee, Elizabeth Ng, and Andrew Tan from the University of California Los Angeles. The project addressed the most common form of bladder cancer, transitional cell carcinoma (TCC), which is the fourth most common and ninth most deadly form of cancer in men. The team developed a high-throughput, flow-through microfluidic platform combined with automated image analysis software, which allows for systematic screening of patients' urine samples in order to noninvasively diagnose TCC. The system provides the pathologist with a quantitative analysis of the sample and an index to differentiate between healthy, low-grade malignancy, and high-grade malignancy. The device has the potential to be applied to a broader range of bodily fluid samples, including blood and pleural fluids; hence it could play a key role in the early diagnosis of various types of cancers.

QuickStitch- Surgical Suturing Device to Improve Fascia Closure was the winner in the category of Therapeutic Devices. The winning team from Johns Hopkins University was comprised of Anvesh Annadanam, Luis Herrera, Daniel Peng, Ang Tu, and Sohail Zahid. QuickStitch is an inexpensive, disposable suturing tool for gastrointestinal surgery that improves safety, efficiency, and consistency in stitching fascia (a collagenous layer underneath the skin that wraps around the internal organs to keep them from pressing against the skin layer). The device aims to improve surgeon performance and patient outcomes by regulating stitch placement and tension, thus helping to avoid the problems of hernias and ischemia that can result from improper stitching after gastrointestinal surgery.

In the category of Technology to Aid Underserved Populations and Individuals with Disabilities the winning project, Low-Cost Spirometer, addressed the lack of devices to measure lung function for the diagnosis and monitoring of respiratory diseases in the developing world. Andrew Brimer, Abigail Cohen, Braden Eliason, Olga Neyman, and Charles Wu from Washington University in St. Louis designed a fluidic oscillating spirometer that costs under $10. The device offers a significant cost reduction compared with traditional spirometers costing $1,000-$2,000, without compromising accuracy or precision. With respiratory diseases like COPD on the rise, the durable low-cost spirometer could improve healthcare in the developing as well as the developed world.

There were a total of 61 entries from 39 different universities with 284 students involved in the projects submitted.

"We like to think of this as the World Series of student engineering, and it has been gratifying to see how this competition stimulated such imaginative thinking, creative designs and overall outstanding achievement," said Roderic I. Pettigrew, Ph.D., M.D., Director of the NIBIB. "We achieved our goal of involving undergraduates in the exciting opportunities biomedical engineers have in developing innovative biomedical technology solutions for problems in health care. The many exceptional projects we received are proof of that."

By holding a design competition open only to undergraduate students, NIBIB intended to encourage the students to compete without reservations of being overpowered by more advanced contenders, explains NIBIB's Zeynep Erim, Ph.D., who manages the DEBUT competition. "It was very rewarding to read the entries and see how the undergraduates stretched their boundaries, formed collaborations " often across departments " and attacked a wide range of unmet clinical needs," she said. "The sophistication of the problems addressed and the innovation of the solutions advanced by the students bode well for the future of biomedical engineering in our country."

Complete project descriptions from the winning student teams along with a list of honorable mentions can be found at http://debut.challenge.gov/.

The rest is here:
NIH announces winners of undergraduate biomedical engineering competition

The Rise And Fall Of The Company That Was Going To Have Us All Using Biofuels

The climb up the steel steps is dizzying--like ascending the tower of a European church, except the steps lead to a platform bolted to the side of a gleaming new chemical plant. Here in Brazil, under a brilliant blue sky, Eduardo Loosli, the plant manager, pauses to explain a vision of the future. "I used to manage a Molson Coors beer manufacturing plant, and its not all that different," he says, leaning on a railing and surveying the scene around us. Directly below is a cityscape of huge stainless-steel tanks. Out beyond the tanks, and stretching far into the distance, are dense greenfields of sugarcane.

Yeast turns grain into beer, Loosli says. Here, in this new plant, genetically engineered yeast created by the plants owners--the California biotech company known as Amyris--turns sugar into liquid fuel. At the end of the platform, Loosli points to two special "seed" tanks. "The yeast enters the system here," he says. When production starts, a glass flask of Amyriss special strain will be poured into each tank, and the yeast will multiply until it becomes a thick, hungry broth. For two weeks, the yeasty stew chews up as much as 1.2 million liters of energy-rich cane syrup. The end product is farnesene, which can be adapted to a seemingly perfect replacement for petroleum-based diesel. Not only does farnesene-based diesel cut pollutants from vehicle exhaust pipes, but since it derives from cane syrup, it is also a renewable resource. These cane fields surrounding the plant are thus the rough equivalent to bottomless oil wells.

Amyriss great innovation is deep inside the genetically modified yeast that chews up the Brazilian sugarcane. The yeast serves as a host for a set of DNA instructions--scientists call the organism a chassis, as if it were a simple platform, waiting for an engine. Depending on their goals, engineers at Amyris can outfit the yeast with a variety of genetic material that tells the yeast how to digest what it is fed. The result is a cell that can (at least in theory) ingest simple sugars and produce virtually anything. Indeed, if the yeast cells work as theyre supposed to, they promise not merely to change the energy industry by producing farnesene. They may also be programmed to transform the way many commodity materials are made. The first step would be petroleum-type materials. Rubber, chemicals, and medicines would follow.

At least thats the idea. Already, in the short lifetime of the biofuels business, Amyris has become legendary--a stand-in for the sectors breathtaking promise and now for its troubling descent. The companys Brazilian plant is referred to as Paraiso, Portuguese for "paradise." It could be more aptly described as a grande esperanca, a great hope. Just a year ago, Amyriss stock price soared to $33 a share. More recently, as the company reported $95 million in losses last quarter, it has plummeted to as low as $1.52. Meanwhile, a once-grand expansion plan has been scaled back. A plant at Sao Martinho, double the size of Paraiso, sits half-complete, vacant as of February. Amyris suspended production at another plant this year.

Everything now rides on success at Paraiso. This summer, as the final bolts were tightened and the last pipes sealed, Loosli readied himself to take command and find out what the plant can do. The future has become a matter of simple economics. If Amyris can produce farnesene efficiently here, the company will gain precious time to perfect its genetic technology. And if not? Then Amyris will likely capsize and pull an entire sector--an entire vision of the future--down with it.

A few weeks before I travel to Brazil to see the Paraiso plant, I discuss Amyriss perilous situation with one of its founders, chief technology officer Neil Renninger. We meet at the companys Emeryville, California, headquarters, in a small lounge decorated with black-and-white photos of Red Sox players and filled with comfortable leather couches. He reminisces about growing up in California--his dad had worked as an engineer at Intel, his mom as a schoolteacher. As he speaks, his slender fingers sometimes search for his iPhone, sometimes hang in the air, and sometimes touch tip-to-tip as he considers a thought.

Circles of exhaustion rim his eyes. His company is ailing and he wears it on his face. Just before my visit, Amyris had announced it had produced a million liters of farnesene in 2011, rather than the 6 million it promised. Its executives declared they would no longer make predictions about future production. "Id be lying to you if I said that I didnt look at the stock price," Renninger admits.

He always knew a startup is a gamble. As an undergraduate at MIT in the mid-1990s, before casino bouncers recognized MIT kids on sight, Renninger played on the institutes notorious Black Jack Team. On nights and weekends, between engineering classes, Renninger traveled to Vegas and Mississippi River casino boats. He wadded up $100,000 of the teams betting money in his pockets, and when a table ran hot, hed clean up. The experience forged him. "The biggest thing I learned at MIT was go ahead and take risks because if you fail, youll land on your feet," he says.

He felt that way about Amyris. Ten years ago, Renninger was working in the lab of Berkeley chemical engineering professor Jay Keasling, a father figure in the field of synthetic biology. Keasling had come to believe that biology would ultimately follow the paths of engineering and computing, and that cells could in time be treated much like small factories, tiny machines whose insides behave like assembly lines. Keaslings idea was that one day a biologist in front of a computer could piece together the virtual genes of a virtual organism, program and test it on a computer model, and then press print. From there, automated machines could produce the actual organism, which would behave exactly as the computer predicted. This is the vision that Renninger signed on to and what he spent years working toward. Today at Amyriss California lab--downstairs from where Renninger is recounting the companys history--a team of 40 scientists works on a computer program called Thumper. Essentially, the program allows scientists to rearrange a yeasts genetic makeup and create new strains; more than 400,000 new strains are screened each week. In a sealed room, the fittest move from plates of colonies to half-liter fermenters--glass containers filled with soups of yeast and sugar, like mocha and cream. The fermenters resemble Cuisinart food processors. From there, the most promising strains are shipped to Brazil.

Back in 2002, Renninger recalls, before any of this was built, Keasling and his colleagues began sharing the details of their work with outside companies. One day, a postdoctoral student under Keasling named Vince Martin said, "We have some good technology and good people. Why dont we do something with it?"

Continue reading here:
The Rise And Fall Of The Company That Was Going To Have Us All Using Biofuels

Virtual Organism Reveals Secrets of Cellular Processes

The Stanford researchers' virtual model of M. genitalium was trained with heterogeneous data and reproduces independent experimental data across multiple cellular functions and scales. It provides a global analysis of the use and allocation of energy in the cell. It also identifies common molecular pathologies underlying single-gene disruption phenotypes.

Bioengineering researchers at Stanford University have created a computational model of an entire organism, according to a report published in Cell.

The Covert Lab incorporated more than 1,900 experimentally observed parameters into their model of the tiny parasite Mycoplasma genitalium.

This model lets them predict cellular behaviors that haven't been observed, as well as new biological processes and parameters.

The organism modeled is Mycoplasma genitalium, or M. genitalium, the smallest known genome that can constitute a cell.

"We synthesized research from the literature, but we also performed our own experiments," team leader Markus Covert, assistant professor of bioengineering at Stanford University, told TechNewsWorld.

The team went through hundreds of reports, and the model also "points out aspects of what we know based on the literature that are not internally consistent," Covert said. "These areas then become tagged as hot spots for further experimentation."

The team used data from more than 900 scientific papers to spell out every molecular interaction known that takes place in the life cycle of M. genitalium. It used that data, together with its own experiments, to create a computational model of the organism that incorporates more than 1,900 experimentally observed parameters.

The model integrates 28 submodels of cellular processes -- cell functions and variables -- grouped in five categories indicated by colors: DNA represented by red; RNA by green; proteins by blue; metabolites by orange; and all other processes by black. Colored lines between the variables and submodels indicate the cell variables predicted by each submodel.

The model was trained with heterogeneous data and reproduces independent experimental data across multiple cellular functions and scales. It provides a global analysis of the use and allocation of energy in the cell. It also identifies common molecular pathologies underlying single-gene disruption phenotypes.

Visit link:
Virtual Organism Reveals Secrets of Cellular Processes

Clemson grows new class of entrepreneurs

Photo by Nathan Gray

Clemson University graduate Riley Csernica helped invent a patented medical device and is a year away from launching her own company.

Photo by Nathan Gray

Riley Csernica works on her laptop in the Iron Yard office at the NEXT Innovation Center in Greenville where she interns. At the age of 21 she has helped invent a patented medical device and is a year away from launching her own company.

GREENVILLE Riley Csernica has at age 21 obtained a bioengineering degree, helped invent a patented shoulder brace and is a year away from launching her own company.

She is one of about 30 students taking part in Clemson University's new master's program in entrepreneurship, which pairs young people building business plans with the legal, financial, organizational and marketing expertise to get them off the ground.

"I was looking for jobs in bioengineering, and nothing was coming up," Csernica said. "Then I thought maybe I should start my own company."

To apply, students had to have an idea for a product or concept that they wanted to bring to the market.

Greg Pickett, the university's associate dean for its Greenville business campus, said he has assembled a team of instructors who have been building wealth and bringing products to the market for decades.

More than 100 business professionals in a range of fields from the Greenville area have also volunteered to serve as student mentors.

Read more:
Clemson grows new class of entrepreneurs

Human Energy Could Power Portable Electronics

Published on: 30th Jul 2012

Technology created by researchers from The Auckland Bioengineering Institute (ABI), which makes it possible to convert human movement into battery power, could in the future enable people to charge their electronic devices while they walk.

This is because artificial muscle generator technology developed by the ABI's Biomimetics Lab can scavenge latent energy from human motion to directly power devices and put power where it's needed.

Dr Tom McKay, Dr Ben O'Brien, Dr Todd Gisby, Associate Professor Iain Anderson and other researchers from the Lab, have been working on the artificial muscle generator technology for the past six years.

Artificial muscle, the main component of the generator, is made of a rubbery material that has mechanical properties similar to human muscle and is capable of generating electricity when stretched.

Dr O'Brien says: "The advantage that we have over our competitors is in the small and soft circuitry that we have developed which controls the artificial muscle. Previously, artificial muscle generators were seen as unpractical to power portable electronic devices because they required bulky, rigid and expensive external electronics."

Our artificial muscle generators because of their circuitry are lightweight, inexpensive and compact so in the future they could easily be incorporated into clothing where they could harvest energy from the wearer's movement, he says.

"It means that people would not have to worry about the batteries on their portable devices dying out and because it would reduce the number and size of batteries required, it would mean less batteries ending up in our landfills."

Several international companies are interested in the Biomimetic Lab's artificial muscle generator technology and in March this year the research was named runner-up in the Excellence in the Field of Environmental Technology Research category at Monaco's CleanEquity investment conference.

The CleanEquity Monaco 2012 conference, sponsored by Prince Albert II, was conceived to accelerate cleantech innovation and implementation and provide expert intelligence on emerging clean technologies.

See the original post here:
Human Energy Could Power Portable Electronics

Human energy to power portable electronics

Technology created by researchers from The Auckland Bioengineering Institute (ABI), which makes it possible to covert human movement into battery power, could in the future enable people to charge their electronic devices while they walk.

This is because artificial muscle generator technology developed by the ABI's Biomimetics Lab can scavenge latent energy from human motion to directly power devices and put power where it's needed.

Dr Tom McKay, Dr Ben O'Brien, Dr Todd Gisby, Associate Professor Iain Anderson and other researchers from the Lab, have been working on the artificial muscle generator technology for the past six years.

Artificial muscle, the main component of the generator, is made of a rubbery material that has mechanical properties similar to human muscle and is capable of generating electricity when stretched.

Dr O'Brien says: "The advantage that we have over our competitors is in the small and soft circuitry that we have developed which controls the artificial muscle. Previously, artificial muscle generators were seen as unpractical to power portable electronic devices because they required bulky, rigid and expensive external electronics."

Our artificial muscle generators because of their circuitry are lightweight, inexpensive and compact so in the future they could easily be incorporated into clothing where they could harvest energy from the wearer's movement, he says.

"It means that people would not have to worry about the batteries on their portable devices dying out and because it would reduce the number and size of batteries required, it would mean less batteries ending up in our landfills."

Several international companies are interested in the Biomimetric Lab's artificial muscle generator technology and in March this year the research was named runner-up in the Excellence in the Field of Environmental Technology Research category at Monaco's CleanEquity investment conference.

The CleanEquity Monaco 2012 conference, sponsored by Prince Albert II, was conceived to accelerate cleantech innovation and implementation and provide expert intelligence on emerging clean technologies.

Follow this link:
Human energy to power portable electronics

NewsdeskHuman energy to power portable electronics

NewsdeskHuman energy to power portable electronics

Technology created by researchers from The Auckland Bioengineering Institute (ABI), which makes it possible to convert human movement into battery power, could in the future enable people to charge their electronic devices while they walk.

This is because artificial muscle generator technology developed by the ABIs Biomimetics Lab can scavenge latent energy from human motion to directly power devices and put power where it's needed.

Dr Tom McKay, Dr Ben OBrien, Dr Todd Gisby, Associate Professor Iain Anderson and other researchers from the Lab, have been working on the artificial muscle generator technology for the past six years.

Artificial muscle, the main component of the generator, is made of a rubbery material that has mechanical properties similar to human muscle and is capable of generating electricity when stretched.

Dr OBrien says: The advantage that we have over our competitors is in the small and soft circuitry that we have developed which controls the artificial muscle. Previously, artificial muscle generators were seen as unpractical to power portable electronic devices because they required bulky, rigid and expensive external electronics.

Our artificial muscle generators because of their circuitry are lightweight, inexpensive and compact so in the future they could easily be incorporated into clothing where they could harvest energy from the wearers movement, he says.

It means that people would not have to worry about the batteries on their portable devices dying out and because it would reduce the number and size of batteries required, it would mean less batteries ending up in our landfills.

Several international companies are interested in the Biomimetric Labs artificial muscle generator technology and in March this year the research was named runner-up in the Excellence in the Field of Environmental Technology Research category at Monacos CleanEquity investment conference.

The CleanEquity Monaco 2012 conference, sponsored by Prince Albert II, was conceived to accelerate cleantech innovation and implementation and provide expert intelligence on emerging clean technologies.

Read more:
NewsdeskHuman energy to power portable electronics

Computer Model Maps Organism's Entire Lifespan Completed

July 22, 2012

Image Caption: The Covert Lab incorporated more than 1,900 experimentally observed parameters into their model of the tiny parasite Mycoplasma genitalium.

redOrbit Staff & Wire Reports Your Universe Online

In what is being called a breakthrough effort for computational biology, researchers from a pair of US universities have successfully completed a software model of an organisms entire lifespan.

The research, which was led by Stanford University Assistant Professor of Bioengineering Markus Covert, used data obtained from over 900 previous scientific papers in order to account for every molecular interaction that occurs during the life cycle of the single-celled Mycoplasma genitalium, Max McClure of the California institution said in a July 19 report.

Coverts team, which also included scientists from the J. Craig Venter Institute (JCVI), then completed a computerized model of the worlds smallest free-living bacterium, which typically lives in the human genital and respiratory tracts, John Markoff of the New York Times wrote on Friday.

According to Stanford, their work, which is detailed in the journal Cell, fulfills a longstanding goal for the field. Not only does the model allow researchers to address questions that arent practical to examine otherwise, it represents a stepping-stone toward the use of computer-aided design in bioengineering and medicine.

Likewise, Markoff reports that experts believe the research represents a tremendous advance in the development of computerized laboratories, which theoretically could conduct thousands of experiments much more quickly than currently possible. It could also help the medical field in their fight against cancer, neurodegenerative diseases, and other serious diseases, while speeding-up the early stages of screening for new compounds and aiding the research of molecular biologists in the process, the Times reporter added.

This achievement demonstrates a transforming approach to answering questions about fundamental biological processes, James M. Anderson, director of the National Institutes of Health (NIH) Division of Program Coordination, Planning and Strategic Initiatives (DPCPSI), said in a statement. Comprehensive computer models of entire cells have the potential to advance our understanding of cellular function and, ultimately, to inform new approaches for the diagnosis and treatment of disease.

The model presented by the authors is the first truly integrated effort to simulate the workings of a free-living microbe, and it should be commended for its audacity alone, a pair of independent commentators, Peter L. Freddolino and Saeed Tavazoie, both of Columbia University, wrote in an editorial accompanying the article, according to Markoff. This is a tremendous task, involving the interpretation and integration of a massive amount of data.

Read more:
Computer Model Maps Organism's Entire Lifespan Completed

Vaccine and antibiotics stabilized so refrigeration is not needed — NIH study

Public release date: 9-Jul-2012 [ | E-mail | Share ]

Contact: Kate Egan NIBIBPress@mail.nih.gov 301-451-0161 NIH/National Institute of Biomedical Imaging & Bioengineering

Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit. This provides a new avenue toward eliminating the need to keep some vaccines and antibiotics refrigerated, which could save billions of dollars every year and increase accessibility to third world populations.

Vaccines and antibiotics often need to be refrigerated to prevent alteration of their chemical structures; such alteration can result in less potent or ineffective medications. By immobilizing their bioactive molecules using silk protein matrices, researchers were able to protect and stabilize both live vaccines and antibiotics when stored at higher than recommended temperatures for periods far longer than recommended.

The research was led by grantees of NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB), David Kaplan, Ph.D., and Jeney Zhang, Ph.D. candidate, at Tufts University School of Engineering in Medford, Mass. The National Eye Institute and the National Institute of Dental and Craniofacial Research at NIH also contributed to this research. The researchers reported on their findings in the online issue of Proceedings of the National Academy of Sciences on July 9, 2012.

"This truly exciting development is the culmination of years of creative exploration and research focused on a major problem in the delivery of health care. Dr. Kaplan and his team have done a masterful job at both understanding the key properties of silk, and applying these insights to a global medical challenge," said NIBIB Director Roderic I. Pettigrew, Ph.D., M.D. "This is also a wonderful validation of the type of team science we see in our Biotechnology Resource and Development Centers and their ability to combine cutting edge science in a number of fields to a variety of health needs."

Pettigrew also points out that the next step is to test it in the field.

Keeping medications cold from production until they are used in treatment is a costly process, accounting for as much as 80 percent of the price of vaccinations. The need for a cold chain has been a difficulty for health care providers, aid organizations, scientists and pharmaceutical companies for decades, especially in settings where electricity is limited. Failures in the chain result in the loss of nearly half of all global vaccines, according to researchers.

In an attempt to solve this problem, Kaplan and his lab have been working extensively with silk films that essentially wrap up the live bioactive molecules present in antibiotics and vaccines. This protects these essential bioactive elements, and so can greatly extend the shelf-life of the medication. Silk is used because it is a protein polymer with a chemistry, structure, and assembly that can generate a unique environment, making it an attractive candidate for the stabilization of bioactive molecules over extended periods of time.

To test their new silk stabilizers, Kaplan's team stored the measles, mumps, and rubella (MMR) vaccines for six months at the recommended 39.2 degrees Fahrenheit, as well as at 77, 98.6 , and 113 degrees Fahrenheit. The results show that encapsulation in the new silk films maintained the potency with minimal loss over time and enhanced stability, even at very high storage temperatures. Similarly, antibiotics entrapped in silk films maintained near optimal activity even at temperatures as high as 140 degrees. In addition, Kaplan's group found that these silk films had the added benefit of protecting one antibiotic against the detrimental effects of light exposure.

View original post here:
Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study

The more obvious ACA – India connection: The windfall to Indian IT

If you are unaware of the Supreme Court decision last month, you are either completely disconnected from the US or are a very successful cave-dweller.

There are several groups benefiting from this decision, all the way from insurance-starved Americans to stir-crazy Tea Party loonies, otherwise known as the GOP. And yes, no matter the amount of fake tears that AdvaMed sheds and its senseless parrots mimic, medical device makers and the pharmaceutical industry are also going to benefit immensely. Sensing huge windfalls, the health insurance industry has also reacted with hidden glee.

However, one important connection has not been made very obvious. Of course, in an election year, who would want to tout the fact that a whole host of Indian IT companies would be making money from a successful US bill? I always knew that EHR/EMR start-ups and Indian companies would benefit from the Affordable Care Act (ACA) -  the numbers seem to be surprisingly low, at least if you were to believe Economic Times.

A luke-warm $5.4bn!


In the truly egregious manner in which most Indian newspaper articles espouse information, analysts who are elevated to "experts" (although the article, linked below does dole out some borderline-pertinent comments) mention that the Indian outsourced software and IT industry would see about  ? 1.2 lakh crores (frustrated by the strange units? Well, that is how the rest of the World feels about FPS) or $5.4bn from the ACA. The analysts from Everest Group, apparently also believe that the true "potential" for this market could be $22bn, which still appears low.


If you look at how big the EHR/EMR and other Medical IT market is going to be over the next decade in the US, one wonders if they mean annually? Understandably, NASSCOM, the Indian IT equivalent of AdvaMed (though not so self-involved) predicts that health based BPO only accounts for 4% of the overall industry, and that it can go up to 11-14% of the total outsourcing business. 


Higher Possibilities or Poor Vision?



While a single article does not a trend make, it would appear that the Indian IT industry is still stuck on "serving" rather than "leading". This is probably why the numbers appear too low to me. The companies are still probably stuck in the "Y2K" mode - calculating how many L1 and H1 visas they can snag and how they can benefit from innovation that comes out of the US. It would appear to me that the Indian IT industry and India in general has much farther to go before they can develop leadership in the true sense. 


It is not that Indians lack creativity, innovation, or simply the power to invent. Leadership has a little more to it by way of ingredients, and I believe this is where the Indian industry with its mob mentality, focused on 90-day cycles is giving in. 


An opportunity for the US that the GOP will take away?

Technically, the lack of Indian leadership in IT is an opportunity for entrepreneurs in the US to look past election-year rhetoric. 


34th time is a charm, no the 35th is, or the 36th...


33 times - that is the number of times the GOP in Congress has tried to repeal the healthcare law. Obviously, this creates unnecessary pall over the healthcare industry, ranging from traditional pharma and medical companies to new and innovative Health 2.0 companies. Over the long term, this could only get worse. Surprisingly, having sided with the GOP on the immensely disastrous attempt to repeal the law, now, on the verge of benefiting from all the effects that ACA will have, I am sure, the industry is tearing its hairs apart over all the uncertainties this constant invective on "Obamacare" is causing to future profits and the very fundamentals of growth in the healthcare industry.


Who will win? India, the US or someone else?


India should take a real close look and see how they have managed to water down a major business bonanza into $22bn or worse $5.4bn. True leadership would mean India turning herself into a leader and direct rather than follow world IT by simply serving as the Global IT bellhop. This might mean fostering indigenous entrepreneurship, doing away with the listless Congress Government, giving the BJP a stern warning that they will go the same route if they don't liberalize; importing Indian talent that has left shores, creating an environment where others would like to come and play - look at Start-Up Chile! There is much work to be done, none of which should involve a lengthy, strategic plan to grovel to others.

As for the US, the democrats need to tout their successes over the past four years, get over the election hoopla and look for true action - reforming legal immigration, realizing that low cost outsourcing is here to stay and fostering innovation. The ACA is only the first step. They should work to put a lid on all the nonsensical lobbyists, stop pussyfooting on efforts to strengthen the FDA and enact other laws key to creating a truly lasting, healthcare solution. Otherwise, if it is not India, it will be someone else!


Look out for more posts on the US and India...


Reference:


http://articles.economictimes.indiatimes.com/2012-07-03/news/32523799_1_healthcare-sector-healthcare-insurance-captive-bpo-unit?utm_source=Digital+Medicine+India&utm_campaign=516ff60956-RSS_EMAIL_CAMPAIGN&utm_medium=email

Source:
http://chaaraka.blogspot.com/feeds/posts/default

International experts gather for AIBN event

The UQ Australian Institute for Bioengineering and Nanotechnology welcomes leading academics from around the world to its first International Conference on BioNano Innovation in July.

Among the conference's plenary speakers will be President of the Chinese Academy of Sciences, Professor Chunli Bai.

Other speakers include Lockheed Martin's Travis Earles; University of Toronto's Professor Peter Zandstra; CSIRO's Dr Ezio Rizzardo; and Harvard University's Dr Kenneth Chien.

The conference will run from July 18-20 at the Brisbane Convention and Exhibition Centre and cover topics such as vaccines, polymer nanostructures, nanomaterials, regenerative medicines and synthetic biology.

Conference convenor and AIBN Group Leader Professor Matt Trau said international experts in the field would gather in Brisbane for the event.

The conference aims to connect scientists, researchers and entrepreneurs in the rapidly-expanding areas of bioengineering and nanotechnology.

The intersection of biology with nanoscience and nanotechnology represents one of the most exciting wellsprings of scientific innovation, Prof Trau said.

Visit http://www.icbni.com.au

Media: Erik de Wit (0427 281 466, 3346 3962 or e.dewit@uq.edu.au)

Follow this link:
International experts gather for AIBN event

American Oriental Bioengineering Announces Appointment of Audit Committee Chairman

NEWARK, N.J., June 18, 2012 /PRNewswire-Asia-FirstCall/ -- The Board of Directors (the "Board") of American Oriental Bioengineering, Inc. , (the "Company", or "we" ), by unanimous written consent appointed Cosimo J. Patti, an independent director of the Board since 2004, as the Chairman of the audit committee of the Board.

Mr. Patti has no family relationships with any of the executive officers or directors of the Company. There have been no transactions in the past two years to which the Company or any of its subsidiaries was, or is to be a party, in which Mr. Patti had or will have a direct or indirect material interest.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Link:
American Oriental Bioengineering Announces Appointment of Audit Committee Chairman

Step closer to understanding childhood degenerative brain disease

Researchers at the Australian Institute for Bioengineering and Nanotechnology (AIBN) are a step closer to understanding and combating the degenerative brain disease ataxia-telangiectasia.

As part of a collaborative project, Associate Professor Ernst Wolvetang's AIBN research group has reprogrammed, for the first time, skin cells from people with the disease so they can study the effectiveness of potential treatments.

The collaborators are from the Queensland Institute of Medical Research (QIMR) and The University of Queensland's Centre for Clinical Research (UQCCR) led by Professor Martin Lavin.

The reprogramming involves taking skin cells, generating pluripotent stem cells and turning them into brain cells for study in the lab.

People with ataxia-telangiectasia develop cancer and brain degeneration because a gene that recognises and repairs DNA damage is defective.

Associate Professor Wolvetang said the ability to reprogram skin cells from children with ataxia-telangiectasia provided a renewable resource to study the neurodegeneration and find medicines to combat it.

The next step is to correct the genetic mutations in the induced pluripotent stem cellsfrom these patients and then turn these corrected stem cells into brain and blood cells and demonstrate these can replace the defective cells that cause the problems in this disease, Associate Professor Wolvetang said.

Delivery of such corrected cells, which is still some years away, or novel drugs discovered using the cells generated in this study may help in treating this disease.

The researchers could start screening medicines in one to two years, but testing in animals would have to be completed before they could be used in humans.

Professor Lavin said the research had benefited from combining his QIMR and UQCCR research group's expertise with that of Associate Professor Wolvetang's AIBN group.

The rest is here:
Step closer to understanding childhood degenerative brain disease